Gilead Sciences, Inc. $GILD Stock Holdings Reduced by Atria Investments Inc

Atria Investments Inc trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 75,057 shares of the biopharmaceutical company’s stock after selling 3,969 shares during the quarter. Atria Investments Inc’s holdings in Gilead Sciences were worth $8,331,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC increased its holdings in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences during the second quarter worth approximately $27,000. Putney Financial Group LLC grew its holdings in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter valued at approximately $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on GILD shares. HSBC raised their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Mizuho upped their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Argus raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $152.42.

Gilead Sciences Stock Up 2.1%

NASDAQ:GILD opened at $154.98 on Friday. The company has a market cap of $192.28 billion, a price-to-earnings ratio of 22.89, a P/E/G ratio of 1.22 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. The stock’s fifty day moving average price is $130.27 and its two-hundred day moving average price is $122.27. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period in the prior year, the business posted $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s payout ratio is presently 46.68%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares in the company, valued at approximately $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 319,391 shares of company stock worth $44,141,101 over the last ninety days. 0.27% of the stock is owned by corporate insiders.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.